.png)
.svg)
The EU Artificial Intelligence Act (EU AI Act), which entered into force in 2024, represents the world’s first comprehensive regulatory framework for artificial intelligence. For digital health and Software as a Medical Device (SaMD) developer, the Act introduces significant new obligations that intersect directly with existing EU MDR requirements and will shape marketing submissions over the coming years.
Key Challenges and Marketing Submission Impact
Under the EU AI Act, most AI-enabled medical devices are classified as high-risk AI systems. This classification imposes mandatory requirements for risk management, data governance, human oversight, transparency, cybersecurity, and post-market monitoring. For marketing submissions, manufacturers must now demonstrate not only MDR conformity but also AI Act compliance, including evidence of dataset representativeness, bias mitigation, model robustness, and documented lifecycle controls. This effectively expands technical documentation and conformity assessment scope, increasing Notified Body scrutiny.
Implications for SaMD Manufacturers
SaMD manufacturers face higher compliance costs, longer submission timelines, and increased cross-functional coordination between regulatory, quality, clinical, and data science teams. Existing AI systems may require retrofitting to meet AI Act requirements, particularly around training data documentation and performance monitoring.
Implementation and Regulatory Pitfalls
Manufacturers will struggle with managing adaptive algorithms, aligning AI change management with locked MDR approvals, and ensuring explainability without compromising IP. Regulators, meanwhile, face challenges in consistently interpreting AI risk classifications, evaluating complex models, and maintaining technical expertise as AI technologies evolve faster than regulatory frameworks.
For more information, visit https://eemedicals.com/
.svg)
.svg)
.svg)